Alchemia is a drug discovery and development company with an FDA approved drug, Fondaparinux, a generic version of the anticoagulant drug; a late stage oncology product pipeline derived from the HyACT® platform within its wholly owned subsidiary, Audeo Oncology, Inc. and a proprietary drug discovery platform, VAST®. HyACT is a platform technology that uses the non-toxic and naturally occurring carbohydrate, hyaluronic acid (HA) as a targeting vehicle for a range of approved anticancer therapeutics. The Company's main product candidate is HA-Irinotecan which is in a clinical trial for the treatment of metastatic colorectal cancer. HA-Irinotecan is also in a clinical trial for small cell lung cancer.Data provided by Mergent, Inc.
|Effective Date||Nov 03, 2004|
|Industry||Pharma. & Biotech.|